odevixibat (Bylvay™)

Policy #  00783
Original Effective Date:  05/09/2022
Current Effective Date:  05/08/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider odevixibat (Bylvay™)‡ for the treatment of pruritis due to progressive familial intrahepatic cholestasis (PFIC) to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility for odevixibat (Bylvay) will be considered when the following criteria are met: Initial:

- Patient has a diagnosis of pruritis due to progressive familial intrahepatic cholestasis (PFIC) Types 1 or 2; AND
  (Note: This specific patient criterion is partially an additional Company requirement for coverage eligibility. Requests for Type III or Type IV PFIC will be denied as not medically necessary** if not met).
- Patient meets one of the following, which confirms the diagnosis of PFIC:
  - Type 1: Presence of mutations in the ATP8B1 gene; OR
  - Type 2: Presence of mutations in the ABCB11 gene; AND
- Patient has the presence of moderate to severe pruritis (per the prescriber); AND
  (Note: This specific patient criterion is partially an additional Company requirement for coverage eligibility. Requests for pruritis severity that are not considered moderate to severe will be denied as not medically necessary** if not met).
- Patient is 3 months of age or older; AND
- Patient has a serum bile acid concentration above the upper limit of the normal reference range for the reporting laboratory; AND

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
odevixibat (Bylvay™)

Policy # 00783
Original Effective Date: 05/09/2022
Current Effective Date: 05/08/2023

(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

- Patient does NOT have a pathologic variant of the ABCB11 gene that predicts non-function or complete absence of bile salt export pump protein (BSEP-3); AND
- Patient has NOT experienced any of the following: cirrhosis, portal hypertension, or history of a hepatic decompensation event (for example: variceal hemorrhage, ascites, hepatic encephalopathy); AND
- Patient has NOT had a liver transplant; AND
  (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).
- Dose of the requested medication will NOT exceed 6 mg (6,000 micrograms) per day; AND
- Dose of the requested medication will NOT exceed 120 micrograms per kilogram per day; AND
- Patient meets one of the following:
  - If the oral pellets are being requested: patient weighs less than 19.5 kg (43 lbs.); OR
  - If the capsules are being requested: patient weighs 19.5 kg or more; AND
- Patient has tried and failed (e.g., intolerance or inadequate response) BOTH GENERIC ursodeoxycholic acid AND GENERIC cholestyramine or colestipol unless there is clinical evidence or patient history that suggests the use of these products will be ineffective or cause an adverse reaction to the patient; AND
  (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).
- Patient has tried and failed (e.g., intolerance or inadequate response) one of the following: GENERIC rifampin, GENERIC naltrexone, or GENERIC sertraline, unless there is clinical evidence or patient history that suggests the use of these products will be ineffective or cause an adverse reaction to the patient.
  (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

Continuation:

- Patient received an initial approval for the requested medication; AND
- Patient has NOT experienced any of the following: cirrhosis, portal hypertension, or history of a hepatic decompensation event (for example: variceal hemorrhage, ascites, hepatic encephalopathy); AND

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
odevixibat (Bylvay™)

Policy # 00783
Original Effective Date: 05/09/2022
Current Effective Date: 05/08/2023

- Patient has NOT had a liver transplant; AND
  (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).
- Dose of the requested medication will NOT exceed 6 mg (6,000 micrograms) per day; AND
- Dose of the requested medication will NOT exceed 120 micrograms per kilogram per day; AND
- Patient meets one of the following:
  - If the oral pellets are being requested: patient weighs less than 19.5 kg (43 lbs.); OR
  - If the capsules are being requested: patient weighs 19.5 kg or more; AND
- Patient has responded to therapy with the requested medication (e.g., decreased pruritis and/or decrease in serum bile acids).
  (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of odevixibat (Bylvay) when the patient has Type III or Type IV progressive familial intrahepatic cholestasis (PFIC) to be not medically necessary.**

Based on review of available data, the Company considers the use of odevixibat (Bylvay) when the patient does NOT have pruritis that is considered to be moderate to severe to be not medically necessary.**

Based on review of available data, the Company considers the use of odevixibat (Bylvay) when the patient has NOT tried and failed other required medications for the condition to be not medically necessary.**

Based on review of available data, the Company considers the use of odevixibat (Bylvay) when the patient does NOT have a serum bile acid concentration above the upper limit of the normal reference range for the reporting laboratory to be not medically necessary.**

Based on review of available data, the Company considers the use of odevixibat (Bylvay) when the patient has had a liver transplant to be not medically necessary.**
odevixibat (Bylvay™)

Policy # 00783
Original Effective Date: 05/09/2022
Current Effective Date: 05/08/2023

Based on review of available data, the Company considers the continued use of odevixibat (Bylvay) when the patient has NOT responded to therapy with the requested medication to be not medically necessary.**

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of odevixibat (Bylvay) when patient selection criteria are not met (except the criterion denoted above as not medically necessary**) to be investigational.*

Background/Overview

Bylvay is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis. The recommended dosage is 40 mcg/kg once daily in the morning with a meal. If there is no improvement after 3 months, the dosage may be increased in 40 mcg/kg increments up to 120 mcg/kg once daily not to exceed a total daily dose of 6 mg.

PFIC is a group of rare, genetic disorders that affects bile acid transporters. There are currently 4 types of PFIC: Types I, II, III, and IV. An in-depth analysis of each type is beyond the scope of this medical policy. Bylvay clinical studies included Types I and II PFIC. These two types of PFIC are caused by mutations in the ATP8B1 and ABCB11 genes, respectively. As a result of the mutations, retention of bile acids occur within the body. Bile flow is integral for the digestion and absorption of dietary fats, vitamins, and other nutrients. Bile flow also facilitates the elimination of excess cholesterol, bilirubin, waste, and toxins from the body. Due to the retention of bile acids in the body, common clinical manifestations include cholestasis, pruritis, and jaundice. Off-label use of ursodeoxycholic acid, cholestyramine, rifampin, naltrexone, and sertraline are commonly used to alleviate symptoms associated with PFIC. A small study of patients with PFIC using ursodeoxycholic acid demonstrated improvements in liver function, hepatosplenomegaly, and pruritis for the majority of the group. European guidelines even discuss the use of ursodeoxycholic acid in this group of conditions. If pruritis is not relieved by ursodeoxycholic acid, then cholestyramine can be used to deplete the bile acid pool. Rifampin works by increasing the
odevixibat (Bylvay™)

Policy #  00783
Original Effective Date: 05/09/2022
Current Effective Date: 05/08/2023

metabolism and excretion of pruritogens. Studies suggest that sertraline and naltrexone are also
viable options for therapy in these patients. After the exhaustion of pharmacologic agents, surgical
procedures to interrupt the circulation of bile acids are often successful. Currently, Bylvay is the
only FDA approved medication for this condition.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Bylvay was approved in 2021 for the treatment of pruritus in patients 3 months of age and older with
progressive familial intrahepatic cholestasis.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature
generally recognized by the relevant medical community, U.S. Food and Drug Administration
approval status, nationally accepted standards of medical practice and accepted standards of medical
practice in this community, technology evaluation centers, reference to federal regulations, other
plan medical policies, and accredited national guidelines.

The efficacy of Bylvay was evaluated in a 24-week, randomized, double-blind, placebo-controlled
trial (Trial 1). Trial 1 included 62 pediatric patients, aged 6 months to 17 years, with a confirmed
molecular diagnosis of progressive familial intrahepatic cholestasis (PFIC) type 1 or type 2, and
presence of pruritus at baseline. Patients with variants in the ABCB11 gene that predict non-function
or complete absence of the bile salt export pump (BSEP) protein, who had experienced prior hepatic
decompensation events, who had other concomitant liver disease, whose INR was greater than 1.4,
whose ALT or total bilirubin was greater than 10-times the upper limit of normal (ULN), or who
had received a liver transplant were excluded in the trial. Patients were randomized to placebo
(n=20), 40 mcg/kg (n=23), or 120 mcg/kg (n=19) of Bylvay. Bylvay was administered once daily
with a meal in the morning. In patients weighing less than 19.5 kg or patients who could not swallow
the whole capsule, study drug was sprinkled on soft food and then administered orally. Of the 62
drugs, 27% had PFIC type 1, and 73% had PFIC type 2. The mean (standard error [SE]) scratching
score in the 2 weeks prior to baseline was 2.9 (0.08). Baseline mean (SE) eGFR was 164 (30.6)
mL/min/1.73 m². Baseline median (range) ALT, AST, and total bilirubin were 65 (16-798) U/L, 83.5
(32-405) U/L, and 2.2 (0.2-18.6) mg/dL, respectively. In Trial 1, a total of 13 patients discontinued
prematurely either due to no improvement in pruritus (n=11) or due to adverse reactions (n=2); 5/20
odevixibat (Bylvay™)

Policy # 00783
Original Effective Date: 05/09/2022
Current Effective Date: 05/08/2023

(25%) patients discontinued from the placebo arm and 8/42 (19%) patients discontinued from the Bylvay arms. A total of 11 of the 13 patients rolled over to a second trial, Trial 2, to receive Bylvay 120 mcg/kg/day. One patient treated with Bylvay 120 mcg/kg/day withdrew from the trial due to a treatment-emergent adverse event of diarrhea.

Given the patients’ young age, a single-item observer-reported outcome (ObsRO) was used to measure patients’ scratching as observed by their caregiver twice daily (once in the morning and once in the evening). Scratching was assessed on a 5-point ordinal response scale, with scores ranging from 0 (no scratching) to 4 (worst possible scratching). Patients treated with Bylvay demonstrated greater improvement in pruritus compared with placebo. The Bylvay groups had 30.1% to 35.4% (depending on the dose) of assessments scored as 0 or 1 compared to 13.2% of the placebo group.

References

Policy History
Original Effective Date: 05/09/2022
Current Effective Date: 05/08/2023
04/07/2022 Medical Policy Committee review
04/13/2022 Medical Policy Implementation Committee approval. New policy.
04/06/2023 Medical Policy Committee review
04/12/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
Next Scheduled Review Date: 04/2024

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
odevixibat (Bylvay™)

Policy # 00783
Original Effective Date: 05/09/2022
Current Effective Date: 05/08/2023

standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.
odevixibat (Bylvay™)

Policy #  00783
Original Effective Date:  05/09/2022
Current Effective Date:  05/08/2023

NOTICE:  If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE:  Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.